# Symic Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/symic-bio

- Industry: Pharmaceuticals
- Headquarters: Emeryville, US
- Website: www.symicbio.com
- Total disclosed funding: $70M
- Latest round: Series B (May 22, 2017)
- Investors on record: 9

## About

Symic Bio, Inc. is a biotechnology company focused on developing innovative therapies that enhance the safety and efficacy of existing medical treatments, particularly in oncology and cardiovascular health.Founded in 2012 and based in Emeryville, US, Symic Bio, Inc. specializes in creating improved drug formulations. The company has completed 6 deals, with its most recent funding round being a Series B raising USD 30.00 mn led by HEDA Ventures on May 22, 2017. The founder's history is not detailed, and there are no indications of prior companies or subsidiaries associated with Symic Bio.Symic Bio specializes in the development of innovative therapies designed to enhance the safety and efficacy of existing treatments in the medical field. The company’s core product offerings focus on unique therapeutic platforms that leverage their proprietary technology to create improved versions of drugs targeting various medical conditions, including but not limited to cancer and cardiovascular diseases. These offerings are developed to address critical end-use cases such as increasing drug half-life, ensuring targeted delivery, and reducing side effects, which are significant challenges in conventional treatments. Targeted at healthcare providers, pharmaceutical companies, and research institutions, Symic Bio's products are aimed at markets in North America, Europe, and selected regions in Asia, where there is a high demand for advanced therapeutic solutions.Symic Bio's revenue model is primarily based on collaborations, licensing agreements, and partnerships with pharmaceutical companies that are looking to enhance their product portfolios with innovative therapies. The structure typically involves upfront payments for access to Symic Bio's proprietary technology, followed by milestone payments linked to the progress of drug development and eventual royalties on sales of the developed products. The company’s flagship products, developed through these partnerships, are expected to command premium pricing in the market due to their advanced therapeutic benefits. Revenue generation is thus closely tied to the successful advancement of these therapies through clinical trials and into commercial usage, positioning Symic Bio as a critical player in the biopharmaceutical landscape.Following the Series B financing of USD 30.00 mn in May 2017, Symic Bio plans to utilize the funds to further develop its innovative therapies and expand its market presence. The company aims to launch new products targeting critical medical conditions, although specific release dates are not disclosed. Additionally, Symic Bio is looking to expand into new markets, particularly in Europe and Asia, by 2025, to meet the increasing demand for advanced therapeutic solutions. This strategic growth is focused on enhancing their product offerings and strengthening partnerships in the biopharmaceutical sector.

## Funding rounds

- Series B, May 22, 2017, $30M — HEDA Ventures
- Series A, Dec 1, 2015, $25M — Lilly Ventures
- Series A, Jan 5, 2015, $15M — Lilly Ventures, Mitsui Global Investment, InCube Ventures, Mission Bay Capital, Ally Bridge Group, Den Danske Forskningsfond, Purdue Foundry, QB3 Partners

## Investors

- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series A
- InCube Ventures — Series A
- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series A
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series A
- Den Danske Forskningsfond — Series A
- Purdue Foundry — Series A
- QB3 Partners — Series A
- HEDA Ventures (https://capitalatlas.ai/funds/heda-ventures) — Series B